DS-2325a
- Generic Name
- DS-2325a
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 12
- Registration Number
- NCT05979831
- Locations
- 🇫🇷
Saint Louis Hospital, Paris, France
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 24
- Registration Number
- NCT05583669
- Locations
- 🇺🇸
Quotient Sciences -Miami, Miami, Florida, United States
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2023-03-06
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 64
- Registration Number
- NCT05388903
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath